UNITED GUARDIAN INC

Listed Company

UGCIK 0000101295NasdaqNon-AcceleratedSmaller ReportingPerfumes, Cosmetics & Other Toilet PreparationsDelawareFY ends Dec 31

Period

FY 2025

Revenue

—

Net Income

$2.11M

Total Assets

$13.11M

Equity

$11.23M

Shares Out

4.59M

Op. Cash Flow

$1.97M

Business

UNITED GUARDIAN INC manufactures, markets and develops specialty cosmetic ingredients, pharmaceutical products, medical lubricants and sexual wellness ingredients through its Guardian Laboratories division. Its main products include Lubrajel multifunctional hydrogels, medical lubricants, the prescription drug Renacidin and the Natrajel sexual wellness ingredient line, plus ancillary cosmetic additives. The company reports operations as a single business segment organized into four product categories: cosmetic ingredients, pharmaceuticals, medical lubricants and sexual wellness. Its products are sold globally primarily through a network of distributors for cosmetics, full-line drug wholesalers for pharmaceuticals, and direct sales to medical product manufacturers.

Summary from filing dated 2025-03-21

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Net sales	11	12	11	13	14
Cost of sales	5	6	5	6	6
Operating expenses	2	2	2	2	2
Research and development expense	463,644	456,779	463,992	490,770	478,642
Total costs and expenses	8	9	8	9	8
Income from operations	2	4	3	4	6
Investment income	365,308	434,679	306,651	236,695	233,857
Net gain on marketable securities	34,359	26,989	81,095	−1	—
Total other income	399,667	461,668	387,746	−809,550	210,839
Income before provision for income taxes	3	4	3	3	6
Provision for income taxes	537,277	857,582	669,408	658,168	1
Net income	2	3	3	3	5
Earnings per common share (basic and diluted) (in dollars per share)	0.46	0.71	0.56	0.56	1.01
Weighted average shares (basic and diluted) (in shares)	5	5	5	5	5

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	1	2	8	830,452	531,213
Marketable securities	7	8	851,318	6	8
Accounts receivable, net of allowance for credit losses of $17,169 in 2025 and $14,342 in 2024	2	1	2	1	2
Inventories, net	2	1	1	2	1
Prepaid expenses and other current assets	207,839	207,804	191,708	201,846	192,579
Prepaid income taxes	325,163	179,017	176,220	185,228	0
Assets, Current	12	13	12	10	12
Deferred income taxes (net)	0	175,397	50,930	110,544	—
Land	69,000	69,000	69,000	69,000	69,000
Factory equipment and fixtures	5	5	5	5	5
Building and improvements	3	3	3	3	3
Total property, plant, and equipment	8	8	8	8	8
Less: Accumulated depreciation	7	7	7	7	7
Total property, plant, and equipment, net	907,182	956,387	619,195	559,161	658,862
TOTAL ASSETS	13	14	13	11	12
Accounts payable	480,791	425,003	134,449	30,415	410,894
Accrued expenses	1	1	1	1	2
Deferred revenue	12,177	0	15,498	0	190,164
Dividends payable	11,405	21,533	21,265	21,220	20,575
Total current liabilities	2	2	2	1	2
Deferred income taxes, net	207,246	0	—	—	83,222
Total liabilities	2	2	2	—	—
Commitments and Contingencies	—	—	—	—	—
Common stock, $.10 par value; 10,000,000 shares authorized; 4,594,319 shares issued and outstanding at December 31, 2025 and 2024	459,432	459,432	459,432	459,432	459,432
Retained earnings	11	11	11	9	9
Total stockholders equity	11	12	11	9	10
TOTAL LIABILITIES AND STOCKHOLDERS EQUITY	13	14	13	11	12

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Depreciation and amortization	108,200	95,885	105,682	135,396	145,977
Net gain on marketable securities	−34,359	−26,989	−81,095	1	—
Allowance for credit losses	2,827	−2,330	−3,391	−189	6,235
Change in allowance for obsolete inventory	−792	−14,208	−17,000	29,000	—
Deferred income taxes	382,643	−124,467	59,614	−193,766	−68,462
Accounts receivable	161,261	−140,714	−135,872	385,959	−431,883
Inventories	−54,976	−214,281	465,506	−290,223	4,984
Prepaid expenses and other current assets	−35	−16,096	10,138	−9,267	−31,371
Prepaid income taxes	−146,146	−2,797	9,008	−185,228	99,107
us-gaap_IncreaseDecreaseInAccountsPayable	55,788	290,554	104,034	−380,479	379,094
Accrued expenses	−302,985	104,889	40,988	−305,334	263,933
Deferred revenue	12,177	−15,498	15,498	−190,164	190,164
Net cash provided by operating activities	2	3	3	3	5
Acquisition of property, plant, and equipment	−58,995	−433,077	−165,716	−75,179	−116,375
Proceeds from sale of marketable securities	−13	−8	−621,852	−2	−4
Purchase of marketable securities	13	2	6	3	4
Net cash provided by (used in) investing activities	175,343	−7	5	897,562	−183,475
Dividends paid	−3	−3	−459,387	−3	−5
Net cash used in financing activities	−3	−3	−459,387	−3	−5
Net (decrease) increase in cash and cash equivalents	−624,558	−6	7	299,239	−60,231
Taxes paid	300,780	1	600,000	1	1

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro